Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Brainstorm Cell Therapeutics (BCLI) has provided an update.
Brainstorm Cell Therapeutics Inc. announced on April 16, 2024, the resignation of Dr. Stacy Lindborg as Co-Chief Executive Officer effective May 9, 2024. Her departure is amicable and includes a separation agreement with a lump sum bonus and a continued board membership. Concurrently, Dr. Ibrahim B. Dagher was promoted to Executive Vice President and Chief Medical Officer. The company has publicly filed these executive changes, underlining the absence of any disagreements behind these transitions.
See more insights into BCLI stock on TipRanks’ Stock Analysis page.
